Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Posting of Annual Report & Notice of AGM
Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, confirms that the Annual Report and Accounts for the year ended 31 December 2014 ("2014 Annual Report and Accounts"), the Notice of the Annual General Meeting ("AGM") and a Form of Proxy have been posted to shareholders on 27th May 2015.
The AGM is to be held at 11am on 30 June 2015 at Finsgate, 5-7 Cranwood Street, London EC1 V9EE.
A copy of the 2014 Annual Report and Accounts and other documents are available on the Company's website: http://vennlifesciences.com/
Enquiries:
Venn Life Sciences Holdings Plc |
|
Tony Richardson, Chief Executive Officer |
Tel: +353 154 99 341 |
Orla McGuinness, Marketing Manager |
Tel: +33 676931178 |
|
|
Zeus Capital (Nominated Adviser and Broker) |
|
Ross Andrews/Andrew Jones |
Tel: 0161 831 1512 |
Alex Davies |
Tel: 020 7533 7727 |
|
|
Walbrook PR Ltd |
Tel: 020 7933 8787 or venn@walbrookpr.com |
Paul McManus |
Mob: 07980 541 893 |
Lianne Cawthorne |
Mob: 07584 391 303 |
About InnoVenn
InnoVenn (55.6% owned by Venn) is a market development accelerator dedicated to rapidly commercialising proven scientific breakthroughs in the form of products and technologies primarily in Skin Science. These include Labskin the breakthrough research grade human skin testing platform as well as the clinically proven Blemish Control Technology for the professional skincare market. For more information on Innovenn, visit www.innovenn.co.uk
About Venn Life Sciences Limited
Venn Life Sciences is a Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK and Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science. For more information, visit www.vennlifesciences.com.